Skip to main content

Depression, Anxiety

Neurology
0
Pipeline Programs
9
Companies
13
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Neurology is a $26.9B market dominated by a single blockbuster anticoagulant (ELIQUIS), representing a mature but consolidating therapeutic area.

$26.9B marketMature→ Stable30 products15 companies

Key Trends

  • Extreme market concentration: 68% of spending driven by one FXa inhibitor product
  • Psychiatric and migraine therapies emerging as secondary growth drivers
  • High clinical trial activity (8,279 trials) signals continued pipeline development

Career Verdict

Neurology offers solid career stability with good hiring demand, but limited upside growth—best suited for professionals seeking established market positions rather than emerging-area innovation.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1ELIQUISStable
$18.3B
Bristol Myers Squibb·Launch15.0yr
$1.8B
#3BRILINTAStable
$692M
AstraZeneca·Peak10.2yr
#4NUPLAZIDStable
$596M
$530M
Johnson & Johnson·Peak15.5yr

Drug Class Breakdown

FXa Inhibitors (anticoagulant)
$18.3B(68%)

market-defining single product

Dopamine/Serotonin Antagonists (psychiatric)
$2.4B(9%)

stable mature class

P2Y12 Receptor Antagonists (antiplatelet)
$692M(3%)

niche but stable

5-HT2A Inverse Agonists (psychiatric)
$596M(2%)

specialty indication focus

CGRP Receptor Antagonists (migraine)
$931M(3%)

emerging growth segment

Immunomodulators (MS)
$747M(3%)

stable with LOE risk

Other mechanisms
$2.6B(10%)

diverse small products

Career Outlook

Stable

Neurology represents a mature, cash-generative market with limited growth tailwinds but strong hiring stability. The dominance of ELIQUIS creates a bifurcated career landscape: high-opportunity positions in emerging segments (CGRP antagonists, psychiatric therapeutics) and commoditized roles in anticoagulant franchises. Job availability is solid but growth expectations should be tempered relative to oncology or immunology.

Breaking In

Entry-level professionals should target clinical operations or commercial support roles at J&J, AstraZeneca, or Sanofi to build domain expertise in neurology disease states and competitive dynamics.

For Experienced Professionals

Experienced professionals should prioritize emerging mechanism roles (CGRP, tau-targeting programs) or pivot to medtech/neurotech (Stryker, Medtronic) to capture higher growth and salary potential than traditional pharma incumbents.

In-Demand Skills

Medical Science Liaisons (MSL) for specialist engagementClinical trial operations expertisePsychiatric/neurodegenerative disease educationRegulatory affairs (given patent cliff activity)Commercial strategy around branded/generic transitions

Best For

Medical Science LiaisonCommercial Brand Manager (anticoagulant/psychiatric franchises)Clinical Operations ManagerRegulatory Affairs SpecialistClinical Development Manager (CGRP/immunomodulator pipelines)

Hiring Landscape

$100K-$199K

Neurology shows moderate but distributed hiring across pharma and medtech employers, with 4,186 total jobs listed. Commercial functions lead (947 roles, $169K avg), followed by clinical operations (467 roles, $132K avg), indicating bias toward commercialization over R&D. Takeda leads external hiring (762 jobs) with strong representation in contract research and CRO spaces.

4,186
Open Roles
5
Companies Hiring
5
Departments

Top Hiring Companies

762Growing
434Stable
302Stable

By Department

Commercial(23%)
$169K
Clinical Operations(11%)
$132K
Engineering(8%)
$199K
IT(4%)
$100K
Manufacturing(3%)
$170K

Commercial and clinical operations roles dominate, offering stable mid-career positions; engineering roles command premium salaries ($199K), suggesting strong device/neurotech hiring pockets.

Competitive Landscape

9 companies ranked by most advanced pipeline stage

Innovation Pharmaceuticals
3 programs
Building Emotion Awareness and Mental HealthN/A1 trial
The Building Emotional Awareness and Mental HealthN/A1 trial
The Light Building Emotional Awareness and Mental HealthN/A1 trial
Active Trials
NCT05306626Completed140Est. Nov 2022
NCT06455397Recruiting400Est. Jun 2027
NCT07026838Recruiting300Est. Dec 2027
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
2 programs
ALLYN/A1 trial
Multi-Modal Palliative Care InterventionN/A1 trial
Active Trials
NCT05025657Unknown1,000Est. Dec 2025
NCT04773639Completed240Est. Jan 2025
Eppendorf
EppendorfGermany - Hamburg
2 programs
Phone-based Aftercare-CoordinationN/A1 trial
psychodynamic psychotherapyN/A1 trial
Active Trials
NCT02044913Completed218Est. Jun 2015
NCT03333239Unknown420Est. Aug 2023
Verona Pharma
Verona PharmaUK - London
1 program
BifihappyN/A1 trial
Active Trials
NCT03539263Completed39Est. Jun 2017
Linnaeus Therapeutics
Linnaeus TherapeuticsNJ - Haddonfield
1 program
Brief interventionsN/A1 trial
Active Trials
NCT04411771Completed69Est. Jun 2020
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
Catalina Story-Based Web-AppN/A1 trial
Active Trials
NCT04862624Completed56Est. Dec 2021
Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
Enhanced School Mental Health ProgramN/A1 trial
Active Trials
NCT06881342Active Not Recruiting137Est. Aug 2025
Lighthouse Pharmaceuticals
Lighthouse PharmaceuticalsCA - San Francisco
1 program
Integrated Cognitive Behavioral TherapyN/A1 trial
Active Trials
NCT07073521Recruiting45Est. Jul 2027
Oregon Therapeutics
Oregon TherapeuticsFrance - Paris
1 program
KEEPN/A1 trial
Active Trials
NCT05816421Completed283Est. Jan 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Lighthouse PharmaceuticalsIntegrated Cognitive Behavioral Therapy
Human BioSciencesEnhanced School Mental Health Program
Innovation PharmaceuticalsThe Light Building Emotional Awareness and Mental Health
Innovation PharmaceuticalsThe Building Emotional Awareness and Mental Health
Oregon TherapeuticsKEEP
Innovation PharmaceuticalsBuilding Emotion Awareness and Mental Health
Colorado TherapeuticsALLY
Colorado TherapeuticsMulti-Modal Palliative Care Intervention
Angeles TherapeuticsCatalina Story-Based Web-App
Linnaeus TherapeuticsBrief interventions
Eppendorfpsychodynamic psychotherapy
Verona PharmaBifihappy
EppendorfPhone-based Aftercare-Coordination

Clinical Trials (13)

Total enrollment: 3,347 patients across 13 trials

NCT07073521Lighthouse PharmaceuticalsIntegrated Cognitive Behavioral Therapy

Developing Evidence-Based Cognitive Approaches to Improve Adjustment to Vision Loss

Start: Jul 2025Est. completion: Jul 202745 patients
N/ARecruiting
NCT06881342Human BioSciencesEnhanced School Mental Health Program

Evaluating the Feasibility of a School-based Stepped Care Program for Internalizing Symptoms in Adolescents in Pakistan

Start: Mar 2025Est. completion: Aug 2025137 patients
N/AActive Not Recruiting
NCT07026838Innovation PharmaceuticalsThe Light Building Emotional Awareness and Mental Health

Advancing Family Wellbeing Through a Massive Open Online Intervention: The LightBEAM Program

Start: Feb 2025Est. completion: Dec 2027300 patients
N/ARecruiting
NCT06455397Innovation PharmaceuticalsThe Building Emotional Awareness and Mental Health

Building Emotional Awareness and Mental Health (BEAM) 2024-2027

Start: Mar 2024Est. completion: Jun 2027400 patients
N/ARecruiting

Adaptation and Evaluation of the KEEP Model

Start: May 2022Est. completion: Jan 2024283 patients
N/ACompleted
NCT05306626Innovation PharmaceuticalsBuilding Emotion Awareness and Mental Health

Building Emotion Awareness and Mental Health (BEAM): Mothers of Toddlers

Start: Dec 2021Est. completion: Nov 2022140 patients
N/ACompleted

Advocates for All Youth

Start: Jul 2021Est. completion: Dec 20251,000 patients
N/AUnknown
NCT04773639Colorado TherapeuticsMulti-Modal Palliative Care Intervention

Randomized Clinical Trial of a Multi-Modal Palliative Care Intervention

Start: Jan 2021Est. completion: Jan 2025240 patients
N/ACompleted
NCT04862624Angeles TherapeuticsCatalina Story-Based Web-App

Media Project and Health Study - Spanish Version

Start: Nov 2020Est. completion: Dec 202156 patients
N/ACompleted

PCBH With the Addition of Self-help CBT

Start: Feb 2019Est. completion: Jun 202069 patients
N/ACompleted
NCT03333239Eppendorfpsychodynamic psychotherapy

Short-term, Long-term and Cost-effectiveness of Treating Depression and Anxiety Disorders in Children and Adolescents

Start: Dec 2017Est. completion: Aug 2023420 patients
N/AUnknown

Effects of Probiotics on Mood

Start: Dec 2016Est. completion: Jun 201739 patients
N/ACompleted
NCT02044913EppendorfPhone-based Aftercare-Coordination

Randomized-controlled Trial of Aftercare-Coordination by Phone for Depression and Anxiety

Start: Mar 2012Est. completion: Jun 2015218 patients
N/ACompleted

Related Jobs in Neurology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 actively recruiting trials targeting 3,347 patients
9 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.